GAITHERSBURG, Md. (WDVM) — A Gaithersburg-based biotech company has reached a COVID-19 vaccine agreement with the Canadian government.
Novavax will provide Canada with up to 76 million doses of its COVID-19 vaccine. Novavax says it will supply those doses to the Canadian government as early as the second quarter of next year, 2021. A release from Novavax says the company and the Canadian government are working to finalize an advance purchase agreement.
Stanley Erck, the President and CEO of Novavax said in a statement, “we are pleased to work with the Canadian government on supply of our COVID-19 vaccine, an essential step to ensure broad access of our vaccine candidate.”
Back in July, the United States government gave Novavax $1.6 billion to help fund the development of a vaccine as part of Operation Warp Speed. The company has secured over $2 billion in total funding.
The vaccine candidate, NVX-CoV2373, is currently in Phase 2 of clinical trials.
- Washington Patriots look to bounce back in week four against Hedgesville
- “Trust the process”: Hedgesville looks to bring home first win since 2018 against Washington
- President Trump expected to announce Supreme Court Justice pick Saturday
- Montgomery County Fire and Rescue Services shares fire safety tips to the fall and winter seasons
- Montgomery Chamber of Commerce hosts 46th Public Safety Awards